INSTRUCTIONS Breathing new life into COPD management
- To take the test online, go to our secure Web site at http://www.nursingcenter.com/CE/nmie.
- On the print form, record your answers in the test answer section of the CE enrollment form on page 54. Each question has only one correct answer. You may make copies of these forms.
- Complete the registration information and course evaluation. Mail the completed form and registration fee of $21.95 to: Lippincott Williams & Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
- You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
- Registration deadline is August 31, 2013.
DISCOUNTS and CUSTOMER SERVICE
- Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together by mail and deduct $0.95 from the price of each test.
- We also offer CE accounts for hospitals and other health care facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of Nursing made Incredibly Easy!, will award 2.3 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.3 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454.
Your certificate is valid in all states.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Breathing new life into COPD management
GENERAL PURPOSE: To update the professional nurse with current guidelines for care of patients with COPD. LEARNING OBJECTIVES: After reading this article and taking this test, you'll be able to: 1. Describe the pathophysiology and risk factors associated with COPD. 2. Identify effective approaches for managing COPD.
1. Which term isn't included in the GOLD guidelines for COPD?
2. Which condition is associated with alveolar destruction?
a. obstructive bronchiolitis
c. chronic bronchitis
3. Structural changes associated with COPD include
a. increased bronchial goblet cells.
b. decreased alveolar macrophages.
4. Chronic airway inflammation can lead to
a. pulmonary vasodilation.
b. inspiratory airflow obstruction.
c. pulmonary hypertension.
5. Risk factors for COPD include all of the following except
b. air pollution.
c. glucose-6 phosphate dehydrogenase deficiency.
6. Which statement about alpha1 antitrypsin is correct?
a. It's a deficiency that's a risk factor for COPD.
b. It's an inflammatory cytokine.
c. It's primarily produced in the lungs.
7. Carbon monoxide combines with hemoglobin to form
8. The maximal amount of air that can be rapidly and forcefully exhaled after maximal inhalation is
b. tidal volume.
9. A normal FEV1/FVC ratio is greater than or equal to
a. 50% of the predicted value.
b. 60% of the predicted value.
c. 70% of the predicted value.
10. An approach clinicians should use during every patient encounter to identify tobacco users and encourage them to quit is the
a. 5 A's.
b. STAR quit plan.
c. 5 R's.
11. The first step in the plan to help smokers who don't want to quit to stop smoking is to identify the
a. rewards of quitting.
b. roadblocks to quitting.
c. relevance of quitting to the patient.
12. What medications are central to symptom management in COPD?
a. mast cell stabilizers
13. Ipratropium is a short-acting
14. Which statement about adverse reactions to beta2-agonists is correct?
a. They may cause sinus tachycardia.
b. Younger patients have a higher risk of adverse reactions.
c. Oral formulations produce fewer adverse reactions.
15. What best describes theophylline use in patients with COPD?
a. It's currently a mainstay of management.
b. It's typically administered by inhalation.
c. It has a narrow therapeutic window.
16. Glucocorticosteroids for managing patients with COPD
a. may decrease the risk of pneumonia when given by inhalation.
b. are particularly effective when given orally.
c. may induce a steroid myopathy with chronic oral use.
17. The goal of oxygen therapy for COPD is to
a. achieve an Sao2 of at least 90%.
b. reverse the disease process.
c. forestall progression of the disease to stage IV.
18. Which treatment improves the elastic recoil of functional lung tissue?
a. lung volume reduction surgery
b. oxygen therapy
Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.